[Skip to Content]
Christopher Fortner, MD, PhD (photo by Jim Howe)
Christopher Fortner, MD, PhD (photo by Jim Howe)

New cystic fibrosis drug regimen considered a breakthrough treatment

A three-drug combination sold under the brand name Trikafta was approved by the Food and Drug Administration in October for people age 12 and older with cystic fibrosis. Christopher Fortner, MD, PhD, medical director of the cystic fibrosis program at Upstate, describes how this treatment works, its side effects and what it may mean for many of the people with this disease. Cystic fibrosis causes persistent lung infections and limits the ability to breathe over time, among other problems.

11-13-19-fortner.mp3 (23.97 MB) (Click to open in new window or Right-Click to save-as)